Arcellx (ACLX) Depreciation & Amortization (CF) (2021 - 2025)
Arcellx (ACLX) recorded quarterly Depreciation & Amortization (CF) of $1.6 million in Q4 2025, down 10.96% quarter-over-quarter from $1.8 million in Q3 2025, and down 8.27% on a YoY basis from $1.8 million in Q4 2024.
Arcellx (ACLX) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
Arcellx's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 8.27% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $6.7 million (up 28.72% YoY), while the FY2025 annual figure was $6.7 million, up 28.72% from the prior year.
- Depreciation & Amortization (CF) was $1.6 million for Q4 2025 at Arcellx, down from $1.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.8 million in Q3 2025 to a low of $207000.0 in Q1 2021.
- Historically, Depreciation & Amortization (CF) has averaged $813400.0 across 5 years, with a median of $443000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) jumped 198.43% in 2024, then retreated 8.27% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $331000.0 in 2021, then gained by 25.68% to $416000.0 in 2022, then soared by 73.56% to $722000.0 in 2023, then surged by 147.78% to $1.8 million in 2024, then slipped by 8.27% to $1.6 million in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.64 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 826,000.00 |
| Mar 31, 2024 | 826,000.00 |
| Dec 31, 2023 | 722,000.00 |
| Dec 31, 2023 | 722,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Sep 30, 2023 | 447,000.00 |